Literature DB >> 18472787

The Interaction of the Antitumor Complexes Na[trans-RuCl(4) (DMSO)(Im)] and Na[trans-RuCl(4)(DMSO)(Ind)] With Apotransferrin: a Spectroscopic Study.

L Messori1, F Kratz, E Alessio.   

Abstract

The interaction of two antitumor ruthenium(III) complexes,-Na[trans-RuCl(4)(DMSO)(Im)] and Na[trans-RuCl(4)(DMSO)(Ind)]- with human serum apotransferrin (apoTf) was investigated through a number of spectroscopic techniques such as UV-Vis absorption, CD and (1)H NMR spectroscopy. Interestingly, the hydrolysis profiles of these complexes in a physiological buffer are markedly affected by the presence, in solution, of apoTf suggesting the occurrence of a specific interaction of their respective hydrolysis products with the protein. The formation of stable adducts with apotransferrin has been demonstrated by CD spectroscopy, and additional information obtained through (1)H NMR of the hyperfine shifted signals. The bound ruthenium(III) species may be detached from these adducts by addition of excess citrate at low pH. The behavior of the investigated ruthenium(III) complexes with apoTf is compared with that of the recently described and strictly related ru-im and ru-ind antitumour complexes, and discussed in the frame of general strategies of drug targeting.

Entities:  

Year:  1996        PMID: 18472787      PMCID: PMC2365001          DOI: 10.1155/MBD.1996.1

Source DB:  PubMed          Journal:  Met Based Drugs        ISSN: 0793-0291


  3 in total

1.  The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin.

Authors:  Malgorzata Brindell; Iwona Stawoska; Justyna Supel; Andrzej Skoczowski; Grazyna Stochel; Rudi van Eldik
Journal:  J Biol Inorg Chem       Date:  2008-04-26       Impact factor: 3.358

2.  Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.

Authors:  A Bergamo; L Messori; F Piccioli; M Cocchietto; G Sava
Journal:  Invest New Drugs       Date:  2003-11       Impact factor: 3.850

Review 3.  Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity.

Authors:  Claudia Riccardi; Domenica Musumeci; Marco Trifuoggi; Carlo Irace; Luigi Paduano; Daniela Montesarchio
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.